Management of type 2 diabetes mellitus - Role of thiazolidinediones

OBJECTIVE To review evidence supporting use of thiazolidinediones (TZDs) in management of type 2 diabetes mellitus (DM2). QUALITY OF EVIDENCE A MEDLINE search found several randomized controlled trials (level I evidence). No systematic reviews of these trials were found in the Cochrane Library. MAIN MESSAGE Thiazoliclinediones lower hemoglobin A(k) levels by as much as 1.0% to 1.5%. Effects can be seen in as little as 4 weeks, but full lowering takes 6 to 12 weeks. When used in combination with other diabetic agents, such as sulfonylureas and biguanicles, TZDs' hypoglycemic effects appear to be complementary. Thiazolidinediones directly improve insulin sensitivity and recovery of pancreatic beta cell function. Nevertheless, there is no evidence indicating that TZDs are superior to other antidiabetic agents currently available or that TZDs reduce the long-term complications of DM2. CONCLUSION Ongoing trials will further define the role of TZDs in management of diabetic patients. In current practice, cost is often a factor in the decision to prescribe TZDs.